natgillin/translations-raw huggingface dataset:
The jacketed tube of claim 1 wherein the jacket comprises polyamide, polyethylene, ethylene chlorotrifluoroerthlyene or a thermoplastic elastomer cross linking ethylene propylene diene monomer rubber and polypropylene. 
Obložena cijev u skladu s patentnim zahtjevom 1, naznačena time što se obloga sastoji od poliamida, polietilena, etilen-klortrifluoretilena ili termoplastičnog elastomernog umreženog etilen-propilen-dien-monomer-kaučuka i polipropilena.
The method of claim 11, wherein the neutralizing antibody is in a sample selected from the group consisting of purified antibodies, serum and antitoxins. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što je navedeno neutralizirajuće protutijelo prisutno u uzorku koji se bira iz skupine koju čine pročišćena protutijela, serum i antitoksini.
This reconstituted material can then be diluted aseptically into a larger volume of liquid for intravenous infusion e.g. 
Ovaj rekonstituirani materijal se može zatim aseptički razrijediti u veći volumen tekućine za intravenoznu infuziju, na pr.
mounting further profiles (2) by means of the fastening element (4); 
- < montiranje narednih profila (2) pomoću elementa za učvršćivanje (4);
admixing up to about 30 weight percent of a semicrystalline polymer to provide a mixture comprising at least 70 weight percent aliphatic polycarbonate; forming a film from the mixture of step (b); and 
(b) miješanje do oko 30 postotnih težinskih udjela polukristalnog polimera radi dobivanja smjese koja sadržava najmanje 70 postotnih težinskih udjela alifatskog polikarbonata;
A package as claimed in any one of Claims 1 to 5, wherein an outer surface of the connecting tab (16) of the sealing flap (5) is glued by spots of permanent glue (17a) to the inner surface of the lid (7). 
Pakiranje u skladu sa bilo kojim patentnim zahtjevom 1 do 6, naznačeno time što je vanjska površina spojnog jezičca (16) brtvenog kapka (5) zalijepljena točkicama stalnog ljepila (17a) na unutarnju površinu poklopca (7).
Use according to any one of the preceding claims, characterised in that following the addition of said 2-aminoethanol, the suspension conductivity change in µS/cm/pH unit is maintained at a value within 10 %, preferably within 6 %, and more preferably within 3 %, of the suspension conductivity value prior to 2-aminoethanol addition. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time što se nakon dodavanja 2-aminoetanola promjena provodljivosti suspenzije u uS/cm/pH jedinica održava pri vrijednosti unutar 10 %, poželjno unutar 6 %, i poželjnije unutar 3 %, vrijednosti provodljivosti suspenzije prije dodavanja 2-aminoetanola.
The refractory material of claim 13, characterized in that the dispersing agents are selected from the group consisting of polyelectrolytes, polycarboxylates, and superplasticizers, the wetting agents are selected from the group consisting of soaps and ether derivatives, the fluxes are selected from the group consisting of low melting compounds promoting sintering and eutectic mixtures promoting sintering, the non-flux agents for a crack- free heat up are selected from the group consisting of organic fibers and metallic fibers, wherein the fibers are capable of melting and/or decomposing and/or reacting below 100 °C, and wherein the additive for chemical, mechanical or electrical modification of the cement is selected from the group consisting of metal powders, metal fibers, semiconductors, magnetic materials, and organic fiber materials. 
Refraktorni materijal prema zahtjevu 13, naznačen time što su agensi za disperziju odabrani od skupine koja se sastoji od polielektrolita, polikarboksilata i superplastizatora, agensi za vlaženje su odabrani od skupine koja se sastoji od sapuna i derivata etera, fluksevi su odabrani od skupine koja se sastoji od spojeva s niskim talištem koji promoviraju sinteriranje i eutektičkih mješavina koje promoviraju sinteriranje, ne-fluks agensi za zagrijavanje bez pucanja su odabrani od skupine koja se sastoji od organskih vlakana i metalnih vlakana, pri čemu su vlakna sposobna topiti se i/ili raspasti se i/ili reagirati ispod 100"C, 1 pri čemu su aditivi za kemijsku, mehaničku ili električnu modifikaciju cementa odabrani od skupine koja se sastoji od metalnih prašaka, metalnih vlakana, poluvodiča, magnetskih materijala i materijala od organskih vlakana.
The method of claim 1, wherein the step of providing comprises providing at least 1000 L of a culture. 
Postupak prema Zahtjevu 1, gdje korak osiguravanja sadrži osiguravanje najmanje oko 1000 L kulture.
A compound for use in treating elevated intraocular pressure, glaucoma, ocular hypertension, or primary open angle glaucoma in a human, wherein the compound is ((2R,3S,4R,SR)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate. 
HR P20151200 T1 PATENTNI ZAHTJEVI Tvar za uporabu u liječenju povišenog intraokularnog tlaka, glaukoma, okularne hipertenzije, ili primarnog glaukoma otvorenog kuta kod čovjeka, pri čemu je tvar ((2R,3S8,4R,SR)-5-(6-(ciklopentilamino)-9H-purin-9-11)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat.
A method for treating a tumor derived from uterine fibroids in a patient in need thereof, the method comprising the step of administering to the patient an effective amount of 17a-acetoxy-11B-[4-N, N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) or a metabolite thereof selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, wherein the tumor is leiomyomatosis or metastasizing leiomyomatosis. 
Ulipristal acetat (17a-acetoksi-115-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice,
Industrial Applicability The present invention can be utilized for the treatment and/or prophylaxis of an anxiety disorder such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, posttraumatic stress disorder, particular phobia, generalized anxiety disorder or the like. 
Derivat tiazola ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen/a time, da se upotrebljava u liječenju i/ili profilaksi poremećaja anksioznosti koji je odabran od sljedećih: panični poremećaj, agorafobija, opsesivno-kompulzivni poremećaj, socijalna fobija, posttraumatski stresni poremećaj, posebno određena fobija i generalizirani poremećaj anksioznosti.
optionally substituted heterocyclo; and optionally substituted heteroaryl; or R10a and R10b taken together with the carbon atom to which they are attached form a 3- to 8-membered optionally substituted cycloalkyl or a 3- to 8-membered optionally substituted heterocyclo; 
R'*i R'" uzeti zajedno s atomom ugljika za koji su pričvršćeni tvore 3- do 8- člani opcionalno supstituirani cikloalkil ili 3- do 8- člani opcionalno supstituirani heterocikl; rje 1,2,1li 3; sje 1,2, ili 3;
The method also includes operating each of the motors in a manner that imparts reciprocating vertical motion to respective vertically movable members of the first and second linear mechanical actuator systems. Each motor has a reversibly rotatable element that is operatively connected to the vertically movable member of its respective linear mechanical actuator system, thus establishing a fixed relationship between the rotational position of the rotatable element and the vertical position of the vertically movable member. 
HR P20191636 T1 215), gdje svaki motor ima povratno zakretljivi element, radno spojen s okomito pomičnim elementom svojeg odgovarajućeg linearnog mehaničkog aktuatorskog sustava (214, 215), čime se uspostavlja fiksni međuodnos između rotacijskog položaja zakretljivog elementa i okomitog položaja okomito pomičnog elementa; gdje se rad svakog od motora sastoji u omogućavanju naizmjeničnog okomitog pomicanja svakog štapa (252, 253) prve i druge usisne štapne crpke (68, 69).
The polypeptide of any one of claims 1-8 or the composition of claim 9, for use in a method of treating a muscular, neurological or metabolic disorder associated with muscle wasting and/or muscle atrophy, or a bone degenerative disorder. 
Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-13 ili pripravak u skladu s patentnim zahtjevom 14, naznačeni time što su namijenjeni upotrebi u postupku liječenja mišićnog, neurološkog ili metaboličkog poremećaja povezanog s propadanjem mišića i/ili atrofijom mišića, ili degenerativnog poremećaja kostiju.
Use according to claim 19, wherein the psychosis or disease involving psychotic symptoms is schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, bipolar disorder, or mania in bipolar disorder. Use according to any of claims 19-20, further comprising a compound selected from the group consisting of sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant. 
Spoj prema bilo kojem od patentnih zahtjeva 12 do 20 za upotrebu u liječenju shizofrenije, pri čemu se spoj koristi u liječenju shizofrenije u kombinaciji s jednim ili više neuroleptičkih agensa, naznačen time što je jedan ili više neuroleptičkih agensa izabran iz grupe koja sadrži sertindol, olanzapin, risperidon, kvetiapin, aripiprazol, haloperidol, klozapin, ziprasidon i osanetant.
represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, or a trifluoromethyl group; 
Ris predstavlja vodikov atom, halogeni atom, alkilnu skupinu koja ima 1 do 6 ugljikovih atoma, ili trifluorometil skupinu;
A cyclic, cell-penetrating peptide comprising formula IIa, IIb, or IIc for use as a medicament, or or a pharmaceutically acceptable salt thereof, wherein the cargo comprises a therapeutic agent and 
13. Ciklični peptid koji prodire u ćelije koji sadrži formulu Ia, IIb, ili Ilc za upotrebu kao lijek, ano PČ NN O cca noža
Pharmaceutical for use according to claim 3, characterized in that it is an inhalable aerosol with or without propellant, or an inhalable dry powder or an inhalable suspension or an inhalable solution. 
Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 3, naznačen time, da je riječ o aerosolu za inhaliranje sa ili bez potisnog sredstva, suhom prašku za inhaliranje, suspenziji za inhaliranje ili otopini za inhaliranje.
These springs also serve the purpose of constituting the elastic pre-charge when shouldering the rifle. 
Ove opruge također služe u tu svrhu da stvore elastično prednaprezanje kada se puška osloni na rame.
An apparatus according to claim 7, wherein the processor (301) is further configured to selectively simulate to the sender that the recipient is indeed a mobile telecommunication network subscriber based on one or more predetermined criteria. 
Uređaj prema zahtjevu 7, gdje je procesor (301) dalje podešen da selektivno simulira pošiljatelju da je primatelj uistinu pretplatnik mobilne telekomunikacijske mreže na temelju jednog ili više unaprijed određenih kriterija.
According to one aspect of the present invention, said water may have a concentration of at least 5% by weight, such as at least 10% by weight, and preferably at least 20% by weight, such as at least 30% by weight, and even more preferably at least 40% by weight. 
Metoda u skladu s patentnim zahtjevom 55, pri čemu voda ima koncentraciju najmanje 5 % prema težini, kao što je najmanje 10 % prema težini, a poželjno najmanje 20 % prema težini, kao što je najmanje 30 % prema težini, a još poželjnije najmanje 40 % prema težini navedene tekućine.
in case said protein molecule is an antibody molecule, it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr− [ATCC No. 
- u slučaju kada je navedena molekula proteina molekula protutijela, ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
That is, as shown in Figure 6, when a force F1 is applied to the switch 302, the switch 302 moves downward. 
To znači, kako je prikazano na Slici 6, da kada se primjeni sila F na sklopku 302, ona se pomakne dolje.
PTA-5543 in a competitive binding assay. 
PTA-5543 u testu kompetitivnog vezanja.
The process of claims 10-13, wherein the dissolution of cholesterol, or derivatives thereof, in a CF is carried out in a reactor at an approximate pressure of 1 to 30 MPa and an approximate temperature of about 10 to 70 °C, preferably between 10 and 50 °C. 
Postupak iz patentnog zahtjeva 7 ili 8, pri čemu se rastvaranje kolesterola, ili njegovih derivata, u CF izvodi u reaktoru pod odgovarajućim pritiskom od 1 do 30 MPa i približnoj temperaturi od oko 10 do 70 *C, preporučljivo između 10 150 *C. 10.
Use according to claim 1, wherein the method of isolating the biopolymers further comprises the step of: removing extracellular polymeric substances (EPS) from the bacterial cells in the sewage sludge prior to disrupting the bacterial cell walls. 
Uporaba prema zahtjevu 1, naznačena time, da postupak izoliranja biopolimera nadalje obuhvaća sljedeći korak: odstranjivanje izvanstaničnih polimernih tvari (EPS) iz bakterijskih stanica u otpadnom mulju prije uništavanja stijenki bakterijskih stanica.
The series of two resistors 28, 29 form a divider, with an end connected to ground 100 and the other one in series with drop resistor 46, supplying a square-wave voltage with network 10 frequency to a pin of unit 50, that said unit 50 uses for internal timing by counting the line cycles (20ms for 50Hz mains and 16,66ms for 60Hz mains). 
Serijski spoj otpornika 28, 29 tvore djelilo čiji je jedan kraj spojen na masu 100, a drugi spojen u seriju s otpornikom 46, i tako napajaju pin jedinice 50 naponom pravokutnog valnog oblika frekvencije mreže 10, koji ta jedinica 50 koristi kao interno odbrojavanje vremena tako da broji pojedine cikluse (20 ms za mrežu 50 Hz, odnosno 16.67 ms za mrežu 60 Hz).
A tablet with the following composition was produced as described in Example 1: Components 
Kako je opisano u Primjeru 1, proizvedena je tableta slijedećeg sastava: Komponente
The compound for use according to claim 11, wherein said pathology is selected from the group consisting of psychiatric and neurological disorders; neurodegenerative disorders; metabolic disorders; addiction, dependence, abuse relapse and related disorders; bladder and gastrointestinal disorders; hepatic diseases such as steatosis; non-alcoholic steatohepatitis (NASH), liver cirrhosis; alcoholic steatosis; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; obesity; autoimmune hepatitis and encephalitis; pain or reproductive disorders and skin inflammatory and fibrotic diseases. 
Tvar za uporabu u skladu s patentnim zahtjevom 11, pri čemu je navedena patologija odabrana iz grupe koja se sastoji od psihijatrijskih 1 neuroloških poremećaja, neurodegenerativnih poremećaja, metaboličkih poremećaja, loših navika, ovisnosti, relapsa zlouporabe i povezanih poremećaja, poremećaja mjehura i hastrointestinalnih poremećaja, bolesti jetre kao što je steatoza, nealkoholnog steatohepatitisa (NASH), ciroze jetre, alkoholne steatoze, upalnih bolesti, kardiovaskularnih bolesti, neuropatija, glaukoma, spastičnosti, raka, osteoporoze, pretilosti, autoiminog hepatitisa 1 encefalitisa, boli ili reproduktivnih poremećaja i upalnih 1 fibrotičnih bolesti kože.
A composition comprising an immunologically effective amount of the conditional replication defective CMV of claim 1 and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži imunološki efikasnu količinu CMYV s uvjetno defektnom replikacijom prema patentnom zahtjevu 1 i farmaceutski prihvatljiv nosač.
The dietary supplement according to claim 7, wherein Catuaba ranges from 50 mg to 300 mg per dosage unit. 
Nadomjestak prema patentnom zahtjevu 7, naznačen time da je Catuaba u rasponu od 50 mg do 300 mg po jedinici doze.
2, 4, 6, and 8 and a second binding domain selected from the group consisting of: 
2, 4, 618, a druga vežuća domena se bira iz skupine koju čine:
under the treatment of organic base (preferably butyl lithium) in tetrahydrofuran (THF) under an argon atmosphere at the temperature of -78°C and subsequent condensation with aldehyde, of the formula III, affording a silylated derivative of the general formula IV, where n = 5 to 9. 
BG II, gdjen=5do9 iX jel, Br, Clili mesil, u tetrahidrofuranu u atmosferi argona na temperaturi -78*C djelovanjem organske baze kondenzira s aldehidom formule III, hu
Bevacizumab for use of claim 6, wherein said effective amount of bevacizumab is administered initially intravenously over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes. 
Bevacizumab za uporabu prema patentnom zahtjevu 6, naznačen time, da se učinkovita količina bevacizumaba početno daje intravenski tijekom 90 minuta s posljedičnim infuzijama tijekom 60 minuta, a potom 30 minuta.
Any such mutein preferably has a sequence of amino acids sufficiently duplicative of that of a non-immunoglobulin protein comprising at least an Ig-like domain such as IL-18BP, IL6-IL6R, IL-6R and beta-galactosidase, such as to have substantially similar activity to IL-18BP, IL6-IL6R, IL-6R and beta-galactosidase and/or provided that they have preserved at least one Ig-like domain. 
Bilo koji takav mutein poželjno ima sekvenciju aminokiselina koja je prihvatljivi duplikat neimunoglobulinskog proteina koji sadrži barem jednu domenu sličnu imunoglobulinskoj, poput IL-18BP, IL6-IL6R, IL-6R i beta- galaktozidazc, kako bi posjedovao aktivnost koja je značajno slična aktivnosti IL-18BP, IL6-IL6R, IL-6R i beta-galaktozidaze, i/ili uz uvjet da ima sačuvanu barem jednu domenu sličnu imunoglobulinskoj.
A pharmaceutical composition comprising the compound of claim 1, or a salt according to claim 2, and a pharmaceutically acceptable carrier, diluent, or excipient. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što još sadrži farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
A process as claimed in claim 8 in which the process comprises the steps of monitoring the temperature of the heated liquid in the buffer tank and maintaining the temperature of the heated liquid in the buffer tank at a desired temperature. 
Postupak prema zahtjevu 8 gdje taj postupak obuhvaća korake praćenja temperature zagrijane tekućine u međuspremniku i održavanje temperature zagrijane tekućine u međuspremniku na željenoj temperaturi.
An antibody that is specific against a peptide according to any of SEQ ID 24, 26 or 28, or to the chimeric/fusion protein according to claim 19, wherein the antibody preferably is a polyclonal antibody, monoclonal antibody and/or a chimeric antibody. 
Antitijelo koje je specifično za peptid u skladu s SEQ ID NO 3 kada je složena sa zasebnom molekulom HLA, pri čemu je protutijelo po mogućnosti poliklonsko antitijelo, monoklonsko antitijelo 1/ili kimerno antitijelo.
ST1899 (3 g, 0.01 mol), dissolved in anhydrous methylene (120 mL), and dimethylaminopyridine (DMAP, 1.5 g) were placed in an anhydrous flask; ethyl-chloroformiate (10 mL) was added dropwise to the solution. 
ST1899 (3 g, 0,01 mol), otopljen u bezvodnom metilenu (120 ml), te dimetilaminopiridin (DMAP, 1,5 g) stavljeno je u bezvodnu bocu; etil-kloroformiat (10 ml) je dodan kap po kap u otopinu.
a support mounted atop at least one insulator, said base member rotatably mounted on said support. 
montiranje navedenog podupirača na distalnom kraju od najmanje jednog izolatora (12),
For Spearmint Flavour—Allow the cooked mass to stand without stirring for approximately 20 minutes. 
Za aromu nane - ostaviti skuhanu masu da odstoji bez miješanja približno 20 minuta.
preparation of the scopine ester of formula I by transesterification of methyl di(2thienyl)glycolate of formula IV with scopine of formula III in the presence of a substoichiometric amount of a sterically hindered base selected from the group of alkali salts of branched C3 to C5 alkoxides in an inert solvent, 
O i putem trans-esterifikacije metil di(2-tieml)glikolata formule IV sa skupinom formule III u nazočnosti substehiometrijske količine odabrane 1z skupine alkalijskih soli razgrananog C3z do Cs alkoksida u inertnom otapalu, b) izolacije skopin estera formule [, 1 c) kvaternizacije skopin estera formule I s metilbromidom.
The apparatus according to claim 5, wherein the second insulator comprises an extraction facility. 
Uređaj prema jednom od Zahtjeva 5 do 14, naznačen time da drugi izolator sadržava jedinicu za ekstrakciju.
structure/function relationships and/or binding studies), such as references 45 to 52, etc. 
studije odnosa struktura/funkcija i/ili vezivanja), kao što su reference 45-52, i t.d.
The method according to claim 4, wherein amylase is added to the meat substitute food product after the extruder cooking step but before the additional high pressure cooking step. 
Postupak prema bilo kojem od patentnih zahtjeva 5 do 9, naznačen time što se amilaza dodaje teksturiranom prehrambenom proizvodu nakon koraka kuhanja u ekstruzijskom kuhalu ali prije dodatnog koraka kuhanja pod visokim tlakom.
In order to enhance the creation of an electrical path between the two metal plates and through the acoustic intermediate layer 3, preferably an acoustic intermediate layer is used, which is more or less electrically conducting, at least at the predetermined location of the welded joint, for example by mixing conducting particles into the material of the acoustic insulation layer. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što sloj zvučne izolacije, u najmanju ruku na zadanom mjestu zavarenog spoja, je više ili manje električno vodljiv, primjerice, miješanjem vodljivih čestica u materijal sloja zvučne izolacije.
at least one blood sample from said patient is to be collected within the first 3 months of treatment, 
sakuplja barem jedan uzorak krvi od spomenutog pacijenta unutar prva tri mjeseca liječenja,
In another embodiment of the invention component (I) and/or (III) of the inventive peptide contains a modified GLP-1 peptide comprising the amino acid sequence of the following formula III: 
Fuzijski peptid prema patentnom zahtjevu 1, naznačen time da je komponenta (I) modificirani GLP-1 peptid koji sadrži aminokiselinsku sekvencu formule III: Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaal8-Tyr-Leu-
conjugating the GalNAc acid derivative of formula I or the GalNAc acid salt of formula V under peptide coupling conditions with an oligonucleotide. 
b3) konjugiranje derivata GalNAc kiseline formule I ili soli GalNAc kiseline formule V u uvjetima peptidnog spajanja s oligonukleotidom.